Ketamina

La ketamina è stata la prima sostanza psichedelica a entrare nella pratica clinica, sebbene con un meccanismo d’azione e un profilo regolatorio diverso rispetto ad altre molecole attualmente in studio.
In questa sezione trovi raccolti gli articoli dedicati alla ketamina e alla sua variante brevettata, l’esketamina: dagli studi clinici alle riflessioni critiche sull’efficacia, i costi e le implicazioni etiche del suo impiego terapeutico.
Una molecola che ha aperto la strada al rinascimento psichedelico, ma che continua a sollevare domande importanti sulla sostenibilità e l’accessibilità dei nuovi trattamenti.

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
Loo, Colleen et al. “Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.” The British journal of psychiatry : the journal of mental science vol. 223,6 (2023): 533-541. doi:10.1192/bjp.2023.79

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.
Mathai, David S et al. “At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.” Journal of affective disorders vol. 361 (2024): 198-208. doi:10.1016/j.jad.2024.05.131

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Glue, P., Loo, C., Fam, J. et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med 30, 2004–2009 (2024). https://doi.org/10.1038/s41591-024-03063-x

Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
Fountoulakis, Konstantinos N et al. “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.” The American journal of psychiatry vol. 182,3 (2025): 259-275. doi:10.1176/appi.ajp.20240515

Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample.
Moore, Tyler M et al. “Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample.” Journal of affective disorders vol. 381 (2025): 233-241. doi:10.1016/j.jad.2025.04.041

Non sei ancora iscrittə alla newsletter?